Back to Search
Start Over
Immunotherapy combinations for chronic lymphocytic leukemia: advantages and disadvantages
- Source :
- Expert Opinion on Biological Therapy. 23:21-35
- Publication Year :
- 2022
- Publisher :
- Informa UK Limited, 2022.
-
Abstract
- In the last few years, BTK inhibitors, PI3K inhibitors, and venetoclax have been approved for clinical use against chronic lymphocytic leukemia (CLL), both as single agents, and in combination. This article summarizes recent achievements in the treatment of patients with CLL, and pays special attention to novel targeted drugs and monoclonal antibodies (Mabs). A literature search was conducted of the PubMed and Google Scholar databases. Rituximab and obinutuzumab have been combined with chemotherapy, and more recently, with BTK inhibitors, PI3K inhibitors, and venetoclax. These agents have demonstrated high activity in treatment naïve (TN) and relapsed or refractory (RR) CLL. Immunochemotherapy regimens are currently considered in TN younger patients with
- Subjects :
- Pharmacology
Clinical Biochemistry
Drug Discovery
Subjects
Details
- ISSN :
- 17447682 and 14712598
- Volume :
- 23
- Database :
- OpenAIRE
- Journal :
- Expert Opinion on Biological Therapy
- Accession number :
- edsair.doi.dedup.....dcca00d16b3697048315c15bd35e3044